Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
about
Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitisAll that bleeds is not infliximab-refractory ulcerative colitis.European evidence-based Consensus on the management of ulcerative colitis: Current management.Review article: acute severe ulcerative colitis - evidence-based consensus statements.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years.C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up studyThirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort studyReview article: the practical management of acute severe ulcerative colitis.Therapeutic effects of four strains of probiotics on experimental colitis in miceUse of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis.Therapeutic strategies for the management of ulcerative colitis.Therapeutic options in acute severe ulcerative colitis.Selecting appropriate anti-TNF agents in inflammatory bowel disease.Review article: the optimal medical management of acute severe ulcerative colitis.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.The pattern and outcome of acute severe colitis.Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article.Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis.Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis.Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis.European evidence based consensus on surgery for ulcerative colitis.Surgical and medical treatment in patients with acute severe ulcerative colitis.The biologics of ulcerative colitis.Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).Can We Predict the Efficacy of Anti-TNF-α Agents?Hypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case report.Immunoprotective Effect of Probiotic Dahi Containing Lactobacillus acidophilus and Bifidobacterium bifidum on Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice.Surgical treatment of ulcerative colitis in the biologic therapy era.Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.Letter: infliximab in severe ulcerative colitis - is it useful for all patients?Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis.Exploring the ameliorative potential of probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum on dextran sodium sulphate induced colitis in mice.Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study.A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization.Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients.Derivation of a T2-weighted MRI total colonic inflammation score (TCIS) for assessment of patients with severe acute inflammatory colitis-a preliminary study.Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.Oral administration of Lactobacillus paracasei alleviates clinical symptoms of colitis induced by dextran sulphate sodium salt in BALB/c mice.
P2860
Q26771136-489E6DC0-529F-4492-8E12-F53DCF796A58Q33408842-3E16C2AB-6056-4D85-A326-444DFAA3EC46Q34025054-997C2C6B-C095-476E-92E5-9C61C0C43527Q34528270-CD217FBB-8A0F-4FAA-BF6A-0C43F04FCC88Q35026302-5EC6905B-BBF5-4DC6-B6B0-93955D263048Q35026410-657C20A5-7E30-4EBF-BFD9-70A14535DBABQ35745374-A49A47AA-52C4-47DA-BFDB-32B30B823F73Q35882026-6AFDFE1A-9D18-4581-85B8-70FEF9FB26C7Q35883580-3E30242C-ECE4-483A-A45B-9B3FAA929E81Q37122235-8C544859-9424-44B0-B466-0E6EFF247BFCQ37256032-ACF91386-A0F5-4295-B49B-867C17BCE742Q37318035-BD85A3FC-E519-4AAC-911E-7BAD707CE55FQ37345935-5A28EA87-EE31-4CBA-AD65-E1FADFE46914Q37503367-A3121388-D0DA-4D11-9786-ADACB4738EECQ37772188-A114FCF5-2B65-42D5-9066-8876A9AEB195Q37814549-D0FB3EC6-06D9-4D50-B7F1-93D51E74D2E1Q37814560-062C338E-23BE-4D07-A297-7B8518AE451EQ38056526-552C1DFB-AD82-4D36-A6AA-8B1AB7265DE8Q38056807-20B25A77-1570-4A7D-9656-FEEBE9BB3B44Q38204993-14DB278F-B7AD-4FCE-B1B6-34106F151C99Q38240881-E39E6369-D226-4636-9B89-B4DBA775CD80Q38258954-3C4EADA8-B886-4FF3-A753-98B82D6A8909Q38575522-22436A18-0DFA-4CAC-A08D-A5B7334FD512Q39037681-7CA94836-4589-40A9-B7B1-83A03933A603Q40708429-4FAD4789-1C77-4CC7-AF95-6D0BBD7EF19CQ41660559-F17BB2F1-245B-434E-A27A-B1876E1C43D4Q42008025-EB4120C5-F4FC-4C1F-A2C4-23E5A63737E1Q42487704-0C3CBCAD-62F5-434C-B1AC-27570F7DDE6FQ42728456-3E9CC5CE-1E3C-4A13-BAE7-395DB347F17CQ43024877-692A741D-625C-4644-AAB0-AA86FD8D4209Q44188398-48C9AF41-B994-4C4E-A504-1110DC03308CQ44593368-53CB2926-16B2-4478-9E2D-68EA408D5A46Q44979663-EDCD9E01-843C-4C9E-B96F-C97DCBD5C111Q45160532-6C9B02C6-57E0-4A67-9F30-937363DAE4F0Q46130626-4DB1398E-5C36-4E4B-B6A8-07E7141A79D4Q46846798-F50E0735-F79D-4D2A-88FC-890CFE88A0E6Q46875109-0E1BCFCF-0FB5-4983-91BB-493998D9BF15Q51665884-6A270C5E-CC31-4405-9CFB-10F7B7C66E67Q53111236-BCF0A2C4-55E8-451E-B4C6-0460E88896A9Q53535882-6D45104F-0267-489C-B270-BF4B40ED9A0B
P2860
Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
@ast
Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
@en
type
label
Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
@ast
Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
@en
prefLabel
Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
@ast
Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
@en
P2093
P1476
Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
@en
P2093
Jakobovits SL
P304
P356
10.1111/J.1365-2036.2007.03300.X
P407
P577
2007-05-01T00:00:00Z